News
Ingredients

Chondro’Sea© : Essential ingredient of cartilage

 

What is Chondro’Sea© ?

It is a substance with a physiological effect. This ingredient contains more than 90% chondroitin sulphate derived solely from fish cartilage. 

Chondroitin sulphate is a molecule naturally present in the joint cartilage. It plays a crucial role in maintaining elasticity and hydration of cartilage tissue.

What galenic forms are particularly suitable for Chondro’Sea© ?

Chondro’Sea© suits several galenic forms for food supplements: 

  • Tablet (Good compressibility)
  • Liquid (Solubility facilitated by granulation)
  • Sachet
  • Capsule 

What makes Chondro’Sea© a unique ingredient ?

Chondro’Sea© is made from cartilaginous fish from the Pacific Ocean using fishing techniques that preserve our marine environment. Indeed, Chondro’Sea© only uses fishery by-products (skeletons and soft tissue) which are often wrongly discarded. It should be noted that this fishing technique is ecologically responsible and does not use any protected fish species.

The unique characteristics of Chondro’Sea© lie in its manufacturing process, which uses specially-developed technology to achieve better product solubility, in particular.

Recently, Pharmanager began research on Chondro’Sea© with a first in vivo study (rats) showing its excellent bioavailability and a second one proving its efficacy.

The bioavailability study1 revealed surprising results. Indeed, studying the speed at which the chondroitin molecule reaches its maximum absorption in the body is a significant parameter for knowing its onset of action. In other words, the more bioavailable the molecule, the faster it is available for the body to use. Also, it will be less likely to be eliminated through the digestive system.

Chondro’Sea© was compared to another commercially-available chondroitin from a marine source and a bovine chondroitin.

 

Results of the bioavailability study

The results showed that oral absorption of Chondro’Sea© is quick since its concentration in the plasma of mice reached its peak only 30 min after its ingestion compared to the commercially-available marine chondroitin (2.5h-3h) and bovine chondroitin (5h).

 

Chondro’Sea© - studies

*Tmax= the time it takes for the product to reach its peak blood concentration. 

 

The secret behind the high bioavailability of Chondro’Sea© lies in its manufacturing process, which makes it possible to obtain smaller molecules that pass more easily through the intestinal barrier to reach the bloodstream and its target: the cartilage.

 

 The physiological effect observed with Chondro’Sea© suggests an interesting beneficial effect on joints.

 

The efficacy study2 evaluated and compared the efficacy of the Chondro’Sea© formulation. 

3 groups studied: 

  • MIA*+Control
  • MIA+Chondro’sea©
  • MIA+Bovine chondroitin

 

* Intra-articular injection of monoiodoacetate (MIA) makes it possible to mimic accelerated cartilage wear.

 

Chondro’Sea© : MIA injection

Diagram of MIA-induced cartilage wear

 

Results of the efficacy study

Chondro’Sea© : Measurement of cartilage areas

 

This study, which was also carried out on an animal model, shows that deterioration is more marked for the “control” and “bovine chondroitin” groups.

 

Administering Chondro’Sea© seems to slow down MIA-induced cartilage deterioration. 

Chondro’Sea© - studies MIA

The histological sections clearly illustrate better preservation of the cartilage for the “Chondro’Sea©” group.

 

Chondro’Sea© supports cartilage health due to the chondroitin it contains.

 

To conclude :

  • More than 90% chondroitin sulphate of marine origin (cartilaginous fish) 
  • Use of fishery by-products 
  • Protected marine species are not used
  • Production plant 100% dedicated to Chondro’Sea©
  • High bioavailability and improved cartilage preservation proven by in vivo studies on an animal model  
  • Stringent quality control according to the criteria of the European Pharmacopoeia monograph
  • A comprehensive file that is compliant with the French “Substances Order” is made available.

 

1 Sarah Paris-Robidas (October 2019), Évaluation de la biodistribution orale de trois formulations de chondroïtine (Evaluation of the oral biodistribution of three chondroitin formulations). Centre de recherche et de transfert en biotechnologies (TransBioTech Canada) 

2 Sarah Paris-Robidas (April 2020), Évaluation de l’efficacité de la Chondro’sea dans un modèle animal de douleur articulaire (Evaluation of the efficacy of Chondro’sea in an animal model of joint pain). Centre de recherche et de transfert en biotechnologies (TransBioTech Canada) 

 

All of our references

 

To learn more, contact us !

Contact EN
Envoi